Class / Patent application number | Description | Number of patent applications / Date published |
424582000 | Embryonic structure (e.g., embryo or fetus, etc.) | 59 |
20090175954 | Sheet-like composition - A sheet-shaped composition is provided which has an improved preservability and handling readiness, as well as a high flexibility in use. Amnion with trehalose added thereto is utilized. Addition of trehalose improves the flexibility of the amnion, and prevents basal membrane and stratum compactum from being damaged during lyophilization process. | 07-09-2009 |
20090258082 | Dried amnion and method for drying teatment of amnion - The present invention provides a dried amnion which is dried with maintaining tissues of a raw amnion and can be easily stored for a prolonged period of time. An amnion which is dried with maintaining cells and tissues of a raw amnion can be produced by repeating a pressure-reducing operation and a pressure-recovery operation several times, the pressure-reducing operation comprising continuously heating a raw amnion placed in a treatment vessel by a far-infrared heater provided in the treatment vessel and reducing the pressure of the inside of the treatment vessel, and the pressure-recovery operation comprising recovering the reduced pressure of the inside of the treatment vessel with heating the amnion by microwaves irradiated from a microwave heating apparatus provided outside of the treatment vessel, and the amnion is characterized by retaining basement membranes and connective tissues which are constituents of the raw amnion. | 10-15-2009 |
20100124574 | Composition Comprising Parasite Eggs And Methods For Isolation And Storage Of Parasite Eggs - The invention relates to a composition for storage and development of eggs from helminthic parasites, where the composition further comprises a liquid carrier having a pH value of below 7 at a temperature of from 10 C to ambient temperature. The liquid carrier can be sulphuric acid, H | 05-20-2010 |
20110189301 | METHOD FOR PREPARING CONTACT LENS-SHAPED AMNIOTIC DRESSING - The present invention relates to a method for preparing a contact lens-shaped amniotic dressing and a contact lens-shaped amniotic dressing prepared therefrom for treating ocular surface diseases, which does not require the use of sutures or an adhesion material. The inventive contact lens-shaped amniotic dressing is capable of solving the problems associated with suturing an amniotic membrane, e.g., highly delicate surgical techniques of suturing, long surgery time, stitch abscess, granuloma formation, tissue necrosis, and discomfort of patients; and the problems associated with the use of a support, e.g., the elimination of the support by eye blinking, breaking of the support, and discomfort. | 08-04-2011 |
20120015042 | RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE - The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications. | 01-19-2012 |
20120107412 | USE OF CELLULAR EXTRACTS FOR SKIN REJUVENATION - The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts. | 05-03-2012 |
20120107413 | PRE-NATAL MESENCHYMAL STEM CELLS - We describe an pre-natal mesenchymal stem cell obtainable from a pre-natal tissue such as a foetal tissue, a descendent of such a mesenchymal stem cell, a cell culture or a cell line comprising either. The pre-natal mesenchymal stem cell, cell culture or cell line may comprise a cell line F1Ib, F2lb, F3lb, F1ki or F3li. We further describe a conditioned medium conditioned by such a pre-natal mesenchymal stem cell, cell culture or cell line. These may comprise cardioprotective activity, and may in particular be used to treat or prevent a range of cardiac disorders of diseases. | 05-03-2012 |
20120207848 | Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 08-16-2012 |
20120207849 | Amniotic Membrane Preparations and Purified Compositions and Anti-Angiogenesis Treatment - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 08-16-2012 |
20130183387 | Methods for treating pustular conditions of the skin - The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 07-18-2013 |
20130344162 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are composition composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein. | 12-26-2013 |
20140037752 | USE OF CELLULAR EXTRACTS FOR SKIN REJUVENATION - The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts. | 02-06-2014 |
20140186461 | Human Amniotic Membrane Lyophilized Grafts - Described herein are human amniotic membrane tissue grafts derived from the placenta. The grafts are composed of three layers as seen in the amniotic membrane in utero. These grafts are processed using physiologic solutions, lyophilized and terminal sterilized (via gamma irradiation in a frozen state) that thereby preserves the graft in such a manner as to retain the naturally occurring biological properties of the amniotic membrane and offer a sterile graft for transplantation. By dehydration via lyophilization and terminal sterilization, the graft has the advantage of storage at ambient temperatures for prolonged periods of time prior to transplantation. | 07-03-2014 |
20140255508 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are composition composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein. | 09-11-2014 |
20140271910 | Methods for treating urushiol-induced contact dermatitis - The invention is directed to methods for treating urushiol-induced contact dermatitis. Specifically, the invention is directed to treating and reducing inflammation associated with poison ivy, poison sumac and poison oak by administering to a subject suffering from such conditions novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). | 09-18-2014 |
20140302162 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are composition composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein. | 10-09-2014 |
20140342015 | Amniotic Membrane Powder and Methods of Making - The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue. | 11-20-2014 |
20140348940 | Amniotic Membrane Hydrogel and Methods of Making - The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue. | 11-27-2014 |
20140356451 | POLYMER CHELATOR CONJUGATES - Provided herein are biocompatible polymer conjugates comprising a biologically compatible polymer covalently bound to a biologically compatible chelator moiety, which in turn are optionally bound, reversibly, to pharmacologically active metal ions. The biologically compatible polymer may comprise of modified placental tissue grafts composed of at least one membrane, capable of recruiting stem cells in vivo and in vitro. | 12-04-2014 |
20150110892 | USE OF CELLULAR EXTRACTS FOR SKIN REJUVENATION - The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts. | 04-23-2015 |
20150320906 | METHODS OF PREPARING LYOPHILIZED HUMAN TISSUES - Described herein are methods of preparing human amniotic membrane tissue grafts derived from the placenta. The grafts are composed of three layers as seen in the amniotic membrane in utero. These grafts are processed using physiologic solutions, lyophilized and terminal sterilized (via gamma irradiation in a frozen state) that thereby preserves the graft in such a manner as to retain the naturally occurring biological properties of the amniotic membrane and offer a sterile graft for transplantation. By dehydration via lyophilization and terminal sterilization in a frozen state, the graft has the advantage of storage at ambient temperatures for prolonged periods of time prior to transplantation. | 11-12-2015 |
20160129154 | AMNIOTIC MEMBRANE - The invention relates to a preserved amniotic membrane, in particular a vacuum-dried amniotic membrane. It also relates to uses of vacuum-dried amniotic membrane and methods for making a vacuum-dried amniotic membrane. A method of processing an amniotic membrane to provide a vacuum-dried amniotic membrane,comprising the step of vacuum-drying the amniotic membrane Amniotic membrane (AM) is the inner most extraembryonic membrane that surrounds the foetus in a sac of amniotic fluid, functioning as a protective barrier to ascending infection and trauma during pregnancy. | 05-12-2016 |
20160199417 | METHOD OF TREATMENT UTILIZING AN ACELLULAR AMNION DERIVED THERAPEUTIC COMPOSITION | 07-14-2016 |
424583000 | Placenta or umbilical cord | 36 |
20090041855 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES - A therapeutic agent for ophthalmic diseases containing Laennec (trade name) as an active ingredient. Laennec, the active ingredient, exhibits a therapeutic effect on a wide variety of ophthalmic diseases by increasing tears and the like and is highly safe even though it is an animal-derived component. Therefore, the therapeutic agent is applicable to the prevention and/or treatment of various types of ophthalmic diseases, particularly corneal disorders, dry eye, asthenopia, inflammatorily ophthalmic diseases (e.g., meibomian gland dysfunction, Stevens-Johnson syndrome, Sjogren syndrome, uveitis) and ophthalmnic diseases caused by active oxygen (e.g., cataract, glaucoma, age-related macular degeneration, optic disc atrophy). | 02-12-2009 |
20090098214 | SKIN-REVITALIZING COSMETIC COMPOSITION - The invention provides a skin-revitalizing cosmetic composition for alleviating or eliminating skin problems such as dry skin, wrinkles, and age spots, the composition containing a skin-revitalizing agent at high concentration. The skin-revitalizing cosmetic composition contains a skin-revitalizing agent selected from the group consisting of aloe extract, placenta extract, hydrolyzed elastin, hydrolyzed collagen, and sodium hyaluronate, wherein the skin-revitalizing agent is in the form of nanoparticles obtained through a nanoparticle-forming treatment. | 04-16-2009 |
20090123560 | Hematopoietic Stem Cell Proliferation Inducing Agent - Disclosed is a hematopoietic stem cell proliferation inducing agent which comprises a pulverized product of placenta-constituting cells as an active ingredient and can induce/proliferate a hematopoietic stem cell in the peripheral blood. Since the proliferation inducing agent can induce/proliferate a hematopoietic stem cell to increase the amount of hematopoietic stem cells in the peripheral blood, it becomes possible to ensure the increase in the amount of hematopoietic stem cells in the peripheral blood. The proliferation inducing agent can be used for the prevention and treatment of various diseases which are caused or believed to be caused by the decrease in the amount of hematopoietic stem cells (e.g., leukemia, malignant lymphoma, aplastic anemia, Alzheimer's disease, Parkinson's disease, dilated cardiomyopathy, myocardial infarction) and produces extremely small adverse side effects. | 05-14-2009 |
20090304808 | Anti-cancer immune-modulating agent - The present invention discloses a method for the preparation of an anti-cancer composition from umbilical cord tissue and animal embryonic tissues, the latter preferably obtained from different animal classes. The composition obtainable by the method comprises different embryonic antigens and is used in therapy and prophylaxis of any type of cancer. | 12-10-2009 |
20100159025 | SYSTEMICALLY AND LOCALLY ADMINISTERED CELLS FOR NEUROPATHIC PAIN - Methods for treating chronic pain, neuropathic pain or spasticity are provided. Some embodiments are to methods for treatment comprising administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. In some embodiments, administering the cells promotes repair and regeneration of nerves in the patient to decrease chronic pain, neuropathic pain or spasticity. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided. | 06-24-2010 |
20110070313 | METHODS OF INDUCING CELL DIFFERENTIATION WITH PLACENTAL EXTRACTS - Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described. | 03-24-2011 |
20110142956 | USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS - The invention relates to the use of PDE5 inhibitors for treating and/or preventing hypopigmentary disorders. | 06-16-2011 |
20110206776 | METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 08-25-2011 |
20120009271 | METHOD OF DISEASE-INDUCED AND RECEPTOR-MEDIATED STEM CELL NEUROPROTECTION - Stem cells are exposed to disease condition (the OGD stroke model), that mimics the target disease (stroke), allowing the stem cells to exert better neuroprotective effects. Thus, the present technology demonstrates a disease-tailored stem cell therapy. The present invention discloses that the administration of a therapeutically effective amount of amnion derived stem cells concomitantly with a therapeutically effective dose of melatonin provides additive/synergistic neuroprotective effects. Moreover, the present invention offers an equally robust technology employing a receptor-regulated mechanism, whereby stem cells can be enhanced (melatonin treatment) over their basal level (lack of melatonin treatment), facilitating a regulation of stem cells. | 01-12-2012 |
20120141595 | UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS - Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM. | 06-07-2012 |
20120276215 | Therapeutic Conditioned Media - Disclosed are therapeutic compositions useful for treatment of degenerative, autoimmune, inflammatory, and neurological conditions. In one embodiment, clinical conditions are treated by administration of a standardized composition of stem cell, progenitor cell, or cellular supernatant. The invention provides doses of conditioned media that mediate therapeutic effects at concentrations that would not be expected to produce biological effects. | 11-01-2012 |
20130129836 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 05-23-2013 |
20130156863 | METHODS OF PREPARING CHORION TISSUE AND PRODUCTS DERIVED THEREFROM - Disclosed herein, in certain instances, are tissue grafts derived from chorion or amnio-chorion. Further disclosed herein, in certain instances, are use for tissue grafts derived from chorion or amnio-chorion. | 06-20-2013 |
20130195992 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-ANGIOGENESIS TREATMENT - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 08-01-2013 |
20130195993 | PURIFIED AMNIOTIC MEMBRANE COMPOSITIONS AND METHODS OF USE - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 08-01-2013 |
20130195994 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 08-01-2013 |
20130243882 | PHARMACEUTICAL COMPOSITION FOR TREATING SKIN WOUND - The present invention provides a method for treating a skin wound in a subject, which comprises administering the skin wound with a composition comprising umbilical mesenchymal stem cells. More particularly, the composition is used for improving wound healing. | 09-19-2013 |
20130280344 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-INFLAMMATION METHODS - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 10-24-2013 |
20130309317 | FOOD SUPPLEMENT INCREASE CD34 STEM CELLS AND TELOMERASE ACTIVITY - The present invention provides a food supplement, which comprises: a placental extract and an oil; which would promote the proliferation of CD34 | 11-21-2013 |
20130344163 | UMBILICAL CORD PRODUCTS - Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM. | 12-26-2013 |
20140112998 | METHODS OF MODULATING BONE REMODELING - Disclosed herein, in certain instances, are methods of inhibiting osteoclast differentiation, bone resorption, bone formation, and bone remodeling in an individual in need thereof, comprising administering to the individual a composition comprising substantially fetal support tissue product including amniotic membrane and umbilical cord or an extract thereof, or a composition comprising substantially isolated HC-HA complex. | 04-24-2014 |
20140127317 | Methods of Manufacture of Immunocompatible Amniotic Membrane Products - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 05-08-2014 |
20140147511 | METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF - Disclosed herein, are methods of preparing fetal support tissue powders. Further disclosed herein, are methods of using the fetal support tissue powder product. | 05-29-2014 |
20150017255 | METHODS FOR TREATING CARDIAC CONDITIONS - Described herein are compositions and methods of treating a cardiac condition using modified placental tissue or an extract of a placental tissue, capable of recruiting stem cells or promoting healing in vivo and in vitro. | 01-15-2015 |
20150064274 | MICRONIZED PLACENTAL COMPOSITIONS COMPRISING A CHELATOR - Provided herein are micronized placental compositions composed of micronized placental tissue component, such as amnion or chorion and/or filler bound to one or more chelating agents, which in turn are optionally bound, reversibly, to pharmacologically active metal ions. Further provided are methods of making and using the placental compositions. The compositions have numerous therapeutic applications. | 03-05-2015 |
20150328265 | Method Of Using Mitotically Inactivated Stem Cells For Damaged Tissue Repair - The present invention is directed to the use of mitotically and/or lethally inactivated stem cells for the repair of damaged organs and/or tissues. Stem cells are mitotically and/or lethally inactivated and transplanted into damaged tissue. Any form of ex vivo inactivation of stem cells may be used such that the stem cells cannot undergo mitosis or cell division before in vivo application. Mitotically and/or lethally inactivated stem may be used to ameliorate numerous disease, injury, traumatic, ischemic, aging, and/or degenerative conditions in different types of organs and/or tissues. | 11-19-2015 |
20160051591 | METHOD FOR THE SEPARATION OF FUNCTIONAL INGREDIENTS IN PLACENTA - The present invention provides a method for the separation of placenta functional ingredients. By using the supercritical fluid technology, the placenta powder is placed inside an extraction tank, under the predetermined pressure and temperature; the supercritical CO | 02-25-2016 |
20160051730 | PLACENTAL TISSUE GRAFTS PRODUCED BY CHEMICAL DEHYDRATION/FREEZE-DRYING AND METHODS FOR MAKING AND USING THE SAME - Described herein are placental tissue grafts produced by chemical dehydration followed by freeze-drying the placental tissue to produce the tissue graft. The tissue grafts retain their biological properties preferably at the same level as the placental tissues before they are processed. The placental tissue grafts have numerous medical applications. Methods for making the tissue graft compositions are also described herein. | 02-25-2016 |
20160074773 | METHOD FOR SEPARATING AND PURIFING FUNCTIONAL INGREDIENTS FROM PLACENTA USING SUPERCRITICAL FLUID TECHNOLOGY - The present invention provides a method to separate and purify functional ingredients in placenta using supercritical fluid technology, where, placenta extract liquid and supercritical CO | 03-17-2016 |
20160101135 | Method and Composition for Hypothermic Storage of Placental Tissue - A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect. | 04-14-2016 |
20160106785 | UMBILICAL CORD PRODUCTS - Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM. | 04-21-2016 |
20160129050 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 05-12-2016 |
20160129051 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-ANGIOGENESIS TREATMENT - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 05-12-2016 |
20160151424 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-INFLAMMATION METHODS | 06-02-2016 |
20160159847 | METHOD FOR SEPARATING ESTROGEN FROM PLACENTA - The present invention provides a method of separating estrogen from placenta, which uses supercritical fluid technique to load the placenta powder of human body or sheep, pig, deer and other animals into an extraction tank. Under the operating conditions of preset pressure and temperature, supercritical solvent is added into the extraction tank to extract estrogen from placenta, so as to acquire de-estrogen placenta powder and placenta extract liquor. Under the same condition, the de-estrogen placenta extract liquor and supercritical solvent are added by a preset volume flow ratio into an adsorption tank. The estrogen in the placenta extract liquor is adsorbed by the adsorption tank to obtain de-estrogen placenta extract. It is then eluted with ethanol solution by gradient proportion to obtain purified natural estrogen. | 06-09-2016 |
20160184368 | UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS - Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM. | 06-30-2016 |